Hany Salama, MD
Internal Medicine · Saint Louis, MONPI 1619064656
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations.
Across 233 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$758
- AbbVie$623
- Lundbeck LLC$205
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$200
- Biogen$193
- Amgen$181
- plus $2K from 25 others
Across 112 payments — averaging $2460.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$109K
- Currax Pharmaceuticals LLC$105K
- AstraZeneca$40K
- GSK$16K
- Exact Sciences$7K
What the payments were for
- Food & beverage$3,59094%
- Education$2376%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 47 | $758 |
| AbbVie(2 entities) | 48 | $623 |
| Lundbeck LLC | 11 | $205 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $200 |
| Biogen | 6 | $193 |
| Amgen | 13 | $181 |
| Axsome Therapeutics, Inc. | 9 | $180 |
| Amarin Pharma, Inc. | 11 | $172 |
| Teva Pharmaceuticals USA, Inc. | 7 | $170 |
| Novo Nordisk | 9 | $161 |
| Sunovion Pharmaceuticals Inc. | 14 | $137 |
| Vanda Pharmaceuticals Inc. | 5 | $118 |
| Pfizer | 6 | $87 |
| Merck | 5 | $69 |
| Astellas Pharma US Inc | 5 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| AstraZeneca | 3 | $58 |
| Eisai Inc. | 3 | $55 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Exact Sciences | 2 | $45 |
| Gilead | 2 | $39 |
| Neurocrine Biosciences, Inc. | 1 | $33 |
| Optos, Inc. | 2 | $29 |
| Optinose US, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Novartis | 1 | $17 |
| GSK | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Urovant Sciences Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$125
How this compares
$3,827 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 28 | $178,021 |
| Invega SustennaPaliperidone Palmitate | 37 | $135,303 |
| EliquisApixaban | 249 | $80,406 |
| TrulicityDulaglutide | 69 | $79,718 |
| XareltoRivaroxaban | 149 | $33,528 |
| OzempicSemaglutide | 21 | $29,286 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 121 | $24,683 |
| VascepaIcosapent Ethyl | 103 | $24,501 |
| Divalproex Sodium | 711 | $23,690 |
| Paliperidone ErPaliperidone | 40 | $21,156 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $20,640 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $13,533 |
| Chlorpromazine Hcl | 27 | $12,753 |
| MounjaroTirzepatide | 12 | $12,636 |
| MyrbetriqMirabegron | 43 | $12,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $170 | $178,02128 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $15 | $168,831186 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $758 | $102,350499 claims |
| PfizerEliquis | $87 | $80,406249 claims |
| GSKBreo Ellipta, Anoro Ellipta, Incruse Ellipta, Trelegy Ellipta | $16 | $55,286110 claims |
| Novo NordiskOzempic, Fiasp | $161 | $33,42134 claims |
| Astellas Pharma US IncMyrbetriq | $66 | $12,17643 claims |
| AstraZenecaLokelma | $58 | $5,71017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
- Mark ScheperleSaint Louis$89K
- Shiyang ZhangSaint Louis$45K
- Bernard McGuireSaint Louis$37K
- Daniel GaitanSaint Louis$34K
- Nathan FarkasSaint Louis$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.